Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation

scientific article published on 13 December 2011

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.BBMT.2011.12.519
P932PMC publication ID3279570
P698PubMed publication ID22178693
P5875ResearchGate publication ID51897268

P50authorGérard SociéQ19859709
Jeff SzerQ42715070
Stephanie J. LeeQ55979666
P2093author name stringShinichiro Okamoto
Mahmoud Aljurf
Yoshiko Atsuta
Navneet S Majhail
Carmem Bonfim
John R Wingard
Maria Teresa Van Lint
J Douglas Rizzo
Linda J Burns
Stella Davies
Andre Tichelli
Center for International Blood and Marrow Transplant Research (CIBMTR)
European Group for Blood and Marrow Transplantation (EBMT)
Naeem Chaudhri
Adriana Seber
American Society for Blood and Marrow Transplantation (ASBMT)
Asia-Pacific Blood and Marrow Transplantation Group (APBMT)
Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ)
Sociedade Brasileira de Transplante de Medula Ossea (SBTMO)
East Mediterranean Blood and Marrow Transplantation Group (EMBMT),
P2860cites workThird Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportQ27861020
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jawsQ28240354
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveQ28388806
Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective surveyQ29391755
Liver transplantation for severe hepatic graft-versus-host disease: an analysis of aggregate survival dataQ30987544
Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors.Q33179317
Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatmentQ33371313
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantationQ33710708
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phaseQ33813443
Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.Q34036696
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group reportQ34474243
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR)Q34474785
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.Q34528330
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control studyQ34554733
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioningQ34568905
Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantationQ34700473
Endocrine late effects after bone marrow transplantQ34722713
Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation.Q34963618
Long-term survival and late deaths after allogeneic hematopoietic cell transplantationQ35023409
Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 yearsQ35023468
Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatmentQ35737132
Endocrine complications of high-dose therapy with stem cell transplantationQ35763915
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor StudyQ35847602
Late effects after stem cell transplantation (SCT) in children--growth and hormonesQ36090236
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor StudyQ36141716
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow TransplaQ36380493
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care WoQ36424524
Update on ocular graft versus host diseaseQ36561557
Female genital tract graft-versus-host disease: incidence, risk factors and recommendations for managementQ36585735
Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trialsQ36596493
Immunobiology of allogeneic hematopoietic stem cell transplantationQ36665305
Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantationQ36945333
Thyroid function following hematopoietic cell transplantation in children: 30 years' experienceQ37041913
Solid cancers after allogeneic hematopoietic cell transplantationQ37082013
Iron overload in hematopoietic cell transplantationQ37148278
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationQ37201899
Recognizing and managing chronic graft-versus-host diseaseQ37346706
Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphomaQ37356389
Epidemiology of neglected tropical diseases in transplant recipients. Review of the literature and experience of a Brazilian HSCT centerQ37704224
Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and managementQ37741643
Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients.Q37781691
Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host diseaseQ37789530
Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHDQ37791005
Late complications after hematopoietic stem cell transplantationQ37810122
Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantationQ43123519
???Q22306355
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantationQ43579107
Acute left ventricular failure following melphalan and fludarabine conditioningQ43703238
Prospective evaluation of neurological complications after allogeneic bone marrow transplantationQ43994969
Characteristics and correlates of cognitive functioning following bone marrow transplantationQ44458858
Cerebral angiitis in four patients with chronic GVHD.Q48406803
Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantationQ48808996
Bone loss following hematopoietic stem cell transplantation: a long-term follow-up.Q50733914
Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls.Q51988742
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant RQ53260982
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation.Q53537221
High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy.Q53558015
Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older WomenQ56656398
Long-term outcome of hepatitis C infection after bone marrow transplantationQ58034510
Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiationQ72333661
Cataract formation after bone marrow transplantationQ72605106
Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM)Q73497707
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced OsteoporosisQ74242371
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trialQ74389035
Female genital tract graft-versus-host disease following allogeneic bone marrow transplantationQ79157140
Late cardiotoxicity after treatment for Hodgkin lymphomaQ79374548
Chronic kidney disease in long-term survivors of hematopoietic cell transplantQ79751158
Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor StudyQ80151067
Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantationQ80193284
Agenesis and microdontia of permanent teeth as late adverse effects after stem cell transplantation in young childrenQ80993650
Regionally limited or rare infections: prevention after hematopoietic cell transplantationQ84794963
Vaccination of hematopoietic cell transplant recipientsQ84794978
Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. PrefaceQ95826686
P433issue3
P921main subjectAustraliaQ408
P304page(s)348-371
P577publication date2011-12-13
P1433published inBiology of Blood and Marrow TransplantationQ15754328
P1476titleRecommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation
P478volume18

Reverse relations

cites work (P2860)
Q38545052A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies.
Q46921945A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function
Q34267886Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.
Q38777460Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma.
Q40718203Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation.
Q92155614Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents
Q38248359Autologous hematopoietic cell transplantation: an update for clinicians
Q37646861Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents
Q35591760Blood and marrow transplant clinical trials network state of the Science Symposium 2014
Q89674644Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Adults
Q36951682Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study
Q26851957Cardiac toxicity in cancer survivors
Q37624268Cardiovascular disease in survivors of hematopoietic cell transplantation.
Q85942264Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes
Q38262917Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD.
Q38772931Clinical management of genital chronic GvHD.
Q38060559Clinical practice implications of immunizations after pediatric bone marrow transplant: a literature review
Q91049108Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies
Q90124938Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma
Q56641541Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease
Q38557591Coordination of Care in Survivorship After Treatment of Hematological Malignancies-The Journey is Not Over Yet.
Q38797541Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis
Q39026510Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy
Q30240070Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation
Q88426253Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD
Q27021501Delivering care to long-term adult survivors of hematopoietic cell transplantation
Q49570612Detection of secondary malignancy following high-dose chemotherapy in germ cell tumors: prospects and limitations
Q38079076Development of an evidence-based clinical guideline for age-appropriate screening, prevention, and management of bone abnormalities in children post-hematopoietic stem cell transplant
Q54296431Effectiveness of long-term routine pulmonary function surveillance following pediatric hematopoietic stem cell transplantation.
Q35859239Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.
Q37577950Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia
Q92158090Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant
Q38545979Functional hyposplenism after hematopoietic stem cell transplantation
Q34551863Haematopoietic stem cell transplantation for autoimmune diseases
Q36744037Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative
Q58117403Hematopoietic stem cell transplantation and quality of life during the first year of treatment
Q37107428High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for 'late effects' screening and preventive strategies.
Q61798366High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation
Q38797551How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.
Q99241272Immune Reconstitution Disorders: Spotlight on Interferons
Q89915009Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial
Q37509207Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection
Q90184237Impact of a Replacement Algorithm for Vitamin D Deficiency in Adult Hematopoietic Stem Cell Transplant Patients
Q37460433Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation
Q47565618International variations in the use of haematopoietic cell transplantation for haematological malignancies: the effects of national transplant indications tables and differing access to therapies
Q88609459Iodine staining and p16 immunohistochemistry as a novel screening for secondary esophageal neoplasm after hematopoietic stem cell transplantation
Q36783762Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report
Q33605306Late cardiovascular complications after hematopoietic cell transplantation
Q33574136Late effects of blood and marrow transplantation
Q90750941Late infectious complications in hematopoietic cell transplantation survivors: a population-based study
Q47780022Late treatment effects following bone marrow transplant: Efficacy of implementing international guidelines
Q47743601Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation.
Q38798042Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care
Q38667959Long-term complications after hematopoietic cell transplantation
Q34749088Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes
Q39002166Mechanistic approaches for the prevention and treatment of chronic GVHD.
Q37104278Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT
Q38933848Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT.
Q40442400Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors
Q35762578National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pedia
Q38376913National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report
Q36766324National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report
Q38374821National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes
Q46181268National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.
Q38405199National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report
Q30245682National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report
Q26787225Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology
Q93040006Occurrence of long-term effects after hematopoietic stem cell transplantation in children affected by acute leukemia receiving either busulfan or total body irradiation: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) ret
Q93341813Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Wo
Q90371647Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT
Q38541845Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management
Q38160758Osteoporosis after stem cell transplantation
Q30235173Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.
Q50173239Palliative care during and following allogeneic hematopoietic stem cell transplantation
Q40445423Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients
Q37188807Prevalence of hematopoietic cell transplant survivors in the United States
Q39098779Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis.
Q36478727Prognostic Importance of Pretransplant Functional Capacity After Allogeneic Hematopoietic Cell Transplantation
Q48660711Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.
Q50672020Psychosocial supportive care services for haematopoietic stem cell transplant patients; a service evaluation of three UK transplant centres.
Q36676908Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation
Q64074914Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors
Q39289010Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium
Q40563365Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation
Q38628809Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies.
Q50104242Second Malignancies after Hematopoietic Stem Cell Transplantation
Q44366982Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study
Q34325244Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning
Q102379465Secondary oral cancer following hematopoietic cell transplantation
Q28088369Secondary solid cancer screening following hematopoietic cell transplantation
Q37239517Sexual health in hematopoietic stem cell transplant recipients.
Q38071930Surviving the cure: long term followup of hematopoietic cell transplant recipients
Q38350270Survivorship after allogeneic transplantation-management recommendations for the primary care provider
Q100750548Survivorship care for allogeneic transplant patients in the UK NHS: changes centre practice, impact of health service policy and JACIE accreditation over 5 years
Q57477760Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation
Q98195449Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH)
Q30244617The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell [...]
Q48095352Thyroid dysfunction in adult hematopoietic cell transplant survivors: risks and outcomes
Q93231451To D or not to D: vitamin D in hematopoietic cell transplantation
Q91329943Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults
Q89840186Treatment and disease-related complications in multiple myeloma: Implications for survivorship
Q26996051Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients
Q33558733Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation
Q36959899Utilization of collaborative practice agreements between physicians and pharmacists as a mechanism to increase capacity to care for hematopoietic stem cell transplant recipients
Q58605810Vitamin D: is it important in haematopoietic stem cell transplantation? A review

Search more.